Measles and rubella elimination: communicating the importance of vaccination
The goal of this project is to support EU Member States in their fight against measles and rubella. This report should enable Member States to engage in effective, evidence-based risk communication.
The goal of this project is to support EU Member States in their fight against measles and rubella. More specifically, this project aims to:
- dispel the myths about measles vaccination;
- offer scientific, evidence-based corrections of misperceptions on measles
- inform about rubella infections in pregnancy; and
- discuss the risks and benefits of vaccination against rubella for women of childbearing age.
This report should enable Member States to engage in effective, evidence-based risk communication. Information on measles and rubella is presented in a modular fashion, so it can be easily used in customised leaflets, flyers, or web pages. The facts presented in this report are intended to lower the barriers to measles and rubella vaccination and raise awareness for congenital rubella syndrome (CRS), including awareness for ante-natal screenings and post-partum vaccination.
Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA
23 Sep 2021 - This report provides an updated overview of the progress of national COVID-19 vaccination strategies in EU/EEA countries, including updates on: vaccine uptake overall and by target group; current vaccination phases and priority groups, as well as any adjustments made to priority groups during the rollout; vaccination strategies and policies in place; and the use of vaccination certificates and challenges countries face with the rollout and good practices to mitigate these challenges.
Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence
22 Jul 2021 - This document provides a review of evidence on three topics of interest (effectiveness of partial vaccination, immunogenicity and effectiveness of vaccination for previously infected individuals and safety and immunogenicity of heterologous schedules) to inform ongoing decision-making in relation to national vaccination policies and strategies in the European Union and European Economic Area (EU/EEA) countries.